A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

Paroxysmal Nocturnal Hemoglobinuria Clinical Trial

— COMMODORE 3  

Official title:

A Phase III, Multicenter, Single Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04654468
• Other study ID #: YO42311
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 17, 2021
• Est. completion date: February 18, 2028

Study information

• Verified date: May 2024
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will enrol participants aged 12 years or older with a body weight >= 40 kilograms (kg) diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 50 participants will be treated with Crovalimab for at least 24 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 51
• Est. completion date: February 18, 2028
• Est. primary completion date: February 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Body weight >= 40 kg at screening.

• Willingness and ability to comply with all study visits and procedures.

• Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry.

• LDH Levels >= 2x the ULN at screening.

• Participants who have at least four transfusions during 12 months prior to screening (documented in the medical record).

• Presence of one or more of the following PNH-related signs or symptoms within 3 months of screening.

• Vaccination against Neisseria meningitidis serotypes A, C, W, and Y < 3 years prior to initiation of study treatment (Day 1)

• Vaccination against Haemophilius influenzae type B and Streptococcus pneumonia according to national vaccination recommendations.

• For participants receiving other therapies (e.g., immunosuppressants, corticosteroids): stable dose for >= 28 days prior to screening and up to the first drug administration.

• Adequate hepatic and renal function.

• Women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for 46 weeks (approximately 10.5 months) after the final dose of crovalimab.

• Platelet count >=30,000 cubic millimeter (mm^3) at screening

• ANC > 500/µl at screening

Exclusion Criteria:

• Current or previous treatment with a complement inhibitor.

• History of allogeneic bone marrow transplantation.

• History of Neisseria meningitidis infection within 6 months prior to screening and up to first drug administration.

• Known or suspected immune or hereditary complement deficiency.

• Known HIV infection with CD4 count < 200 cells per microlitre (cells/µl) within 24 weeks prior to screening.

• Infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 28 days prior to screening and up to the first drug administration, or oral antibiotics within 14 days prior to screening and up to the first drug administration.

• Active systemic bacterial, viral, or fungal infection within 14 days before first drug administration.

• Presence of fever (>= 38°C) within 7 days before the first drug administration.

• Splenectomy < 6 months before screening.

• History of malignancy within 5 years prior to screening and up to the first drug administration.

• Pregnant or intending to become pregnant during the study or within 46 weeks (10.5 months) after the final dose of study treatment.

• Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever is greater.

Related Conditions & MeSH terms

• Hemoglobinuria
• Hemoglobinuria, Paroxysmal
• Paroxysmal Nocturnal Hemoglobinuria

Intervention

Drug:
• Crovalimab
Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg). Dosing schedule will be as described above.

Locations

Country	Name	City	State
China	West China Hospital, Sichuan University	Chengdu
China	Guangdong General Hospital	Guangzhou
China	Tianjin Medical University General Hospital	Tianjin
China	Institute of Hematology and Hospital of Blood Disease	Tianjin City
China	Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan City

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Percentage of Participants With Hemolysis Control	A Generalized Estimating Equation (GEE) was used to estimate the population-average percentage of the participants with hemolysis control (measured by lactate dehydrogenase (LDH) =1.5 x upper limit of normal (ULN)) from Week 5 to Week 25 taking account of the intra-patient and inter-patient correlation between LDH control statuses across visits. The dependent variable was the binary indicator for hemolysis control. Independent variables are categorical effects of visits, continuous baseline LDH.	From Week 5 up to Week 25
Primary	Difference in Percentage of Participants With Transfusion Avoidance (TA) From Baseline Through Week 25 and Within 24 Weeks Prior to Screening	TA was defined as participants who were packed red blood cell (pRBC) transfusion-free and did not require transfusion per protocol-specified guidelines. TA within 24 weeks prior to screening was based on the pRBC transfusion history in the medical records. Reported in this outcome measure is the difference in the percentage of participants between "baseline through Week 25" and "within 24 weeks prior to screening". 95% Confidence Interval (CI) for the difference between the percentage of participants with transfusion avoidance between Pre-screening and Post-baseline is calculated using the Newcombe method.; Screening= Day -28 to Day -1 and Baseline= Day 1.	24 Weeks Prior to Screening, Baseline to Week 25
Secondary	Percentage of Participants With Breakthrough Hemolysis (BTH)	BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath [dyspnea], anemia [hemoglobin < 10 grams per deciliter (g/dL)], major adverse vascular event [MAVE, including thrombosis], dysphagia, or erectile dysfunction) in the presence of elevated LDH =2xULN after a prior LDH reduction to =1.5xULN from the start of study treatment. As pre-specified in the SAP participants withdrawing before Week 25 were deemed to have experienced a BTH event. Percentages have been rounded off to the first decimal point.	Baseline, Week 25
Secondary	Percentage of Participants With Stabilized Hemoglobin	Stabilized hemoglobin was defined as avoidance of a =2 g/dL decrease in hemoglobin level from baseline, in the absence of transfusion. As pre-specified in the SAP participants withdrawing before Week 25 were deemed to not have hemoglobin stabilization.	Baseline, Week 25
Secondary	Change From Baseline in Fatigue in Adults Aged >=18 Years	Fatigue was assessed using functional assessment of chronic illness therapy-fatigue (FACIT-F) scale. FACIT-F is a self-assessment questionnaire with a 7-day recall period and 13 items evaluating fatigue and its impact on daily life activities. Items are scored on a response scale that ranges from 0 ("not at all") to 4 ("very much so"). Relevant items are reverse scored, and all the items are summed to create a total score range from 0 to 52, with 0 being the worst possible score and 52 being the best possible score. A higher score indicates low fatigue severity. A positive mean change indicates improvement. FACIT-F was assessed in adult participants only. FACIT-F assessment was unintentionally missed in the Schedule of Activities (SoA) table, which site used to guide the assessments at each timepoint. Therefore, data were not collected at Week 25.	Baseline, Week 2, Week 5, Week 9, Week 17, Week 25
Secondary	Percentage of Participants With Adverse Events (AEs)		Up to 7 years
Secondary	Percentage of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, and Infections (Including Meningococcal Meningitis)		Up to 7 years
Secondary	Percentage of Participants With Adverse Events (AEs) Leading to Study Drug Discontinuation		Up to 7 years
Secondary	Trough Serum Concentration of Crovalimab Over Time		Up to 7 years
Secondary	Serum Concentrations of Crovalimab		Up to 7 years
Secondary	Percentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab		Up to 7 years
Secondary	Terminal Complement Activity as Measured by Liposome Immunoassay (LIA)		Up to 7 years
Secondary	Change Over Time in Total and Free C5 Concentration		Up to 7 years
Secondary	Observed Value in Absolute Reticulocyte Count		Up to 7 years
Secondary	Observed Value in Free Hemoglobin		Up to 7 years
Secondary	Observed Value in Haptoglobin		Up to 7 years
Secondary	Percent Change From Baseline in Absolute Reticulocyte Count		Baseline, Week 25
Secondary	Percent Change From Baseline in Free Hemoglobin		Baseline, Week 25
Secondary	Percent Change From Baseline in Haptoglobin		Baseline, Week 25